Focus 1: Efficacy of Combined Immunologic Approaches to Target the Viral Reservoir

We believe that combined immunologic strategies will likely be required to eliminate virally-infected cells and to achieve long-term immune control of persistent viral reservoirs. Identifying the immunologic strategies that are effective is the goal of the I4C Collaboratory.

  • Specific Aim 1: To evaluate two leading therapeutic vaccines in ART-suppressed, HIV-1-infected humans treated during acute HIV-1 infection (Ad26/MVA mosaic vaccine, conserved HIV-1 peptide-pulsed DC vaccine).
  • Specific Aim 2: To evaluate the combination of bnMAbs and a therapeutic vaccine in ART-suppressed, SHIV-infected rhesus monkeys.
  • Specific Aim 3: To evaluate the combination of optimal bnMAbs and a therapeutic vaccine in ART-suppressed, HIV-1-infected humans treated during both acute and chronic HIV-1 infection

Focus 2: Mechanisms and Next Generation Strategies to Target the Viral Reservoir

We will explore the hypothesis that our bnMAbs, therapeutic vaccines, and LRAs will eliminate a subset of reservoir cells in ART-suppressed, SHIV-infected rhesus monkeys and that these mechanistic data will facilitate the development of improved HIV-1 cure strategies.

  • Specific Aim 1: To define the mechanism of action of leading bnMAbs, therapeutic vaccines, and LRAs in depleting the viral reservoir in ART-suppressed, SHIV-infected rhesus monkeys.
  • Specific Aim 2: To develop more effective bnMAbs for reservoir depletion.
  • Specific Aim 3: To test an improved HIV-1 cure strategy in ART-suppressed, SHIV-infected rhesus monkeys.